KEYNOTE-789: Chemotherapy With or Without Pembrolizumab for TKI-Resistant Nonsquamous NSCLC

Video

Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
1 KOL is featured in this series.
Related Content